In the last week, the Biotech industry is up 6.5%, with Innovent Biologics up 4.1%. Meanwhile, ImmuneOnco Biopharmaceuticals (Shanghai) actually underperformed within the industry, shrinking 17% in the last week. In the past year, the industry is down 26%. Earnings are forecast to grow by 34% annually.
Has the Hong Kong Biotech Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Wed, 07 Aug 2024 | HK$328.8b | HK$50.3b | -HK$19,745,832,215.85 | 11.5x | -16.7x | 6.5x |
Fri, 05 Jul 2024 | HK$316.6b | HK$49.6b | -HK$19,434,376,607.24 | 11.7x | -16.3x | 6.4x |
Sun, 02 Jun 2024 | HK$340.5b | HK$49.8b | -HK$19,538,408,792.63 | 12x | -17.4x | 6.8x |
Tue, 30 Apr 2024 | HK$360.3b | HK$49.7b | -HK$19,502,930,130.42 | 12.1x | -18.5x | 7.3x |
Thu, 28 Mar 2024 | HK$342.7b | HK$49.5b | -HK$19,178,748,110.55 | 13.7x | -17.9x | 6.9x |
Sat, 24 Feb 2024 | HK$340.8b | HK$46.8b | -HK$20,173,383,442.48 | 17x | -16.9x | 7.3x |
Mon, 22 Jan 2024 | HK$339.3b | HK$47.0b | -HK$20,275,134,851.00 | 16.3x | -16.7x | 7.2x |
Wed, 20 Dec 2023 | HK$395.7b | HK$47.0b | -HK$20,266,729,302.00 | 17.4x | -19.5x | 8.4x |
Fri, 17 Nov 2023 | HK$410.1b | HK$45.2b | -HK$18,711,404,914.00 | 17.9x | -21.9x | 9.1x |
Sun, 15 Oct 2023 | HK$400.9b | HK$44.9b | -HK$19,108,661,851.00 | 14.7x | -21x | 8.9x |
Tue, 12 Sep 2023 | HK$413.7b | HK$45.0b | -HK$18,950,523,216.00 | 15.8x | -21.8x | 9.2x |
Thu, 10 Aug 2023 | HK$389.0b | HK$35.4b | -HK$23,304,596,400.00 | 22.4x | -16.7x | 11x |
Sat, 08 Jul 2023 | HK$397.5b | HK$35.4b | -HK$23,261,472,051.00 | 24.6x | -17.1x | 11.2x |
Mon, 05 Jun 2023 | HK$415.9b | HK$36.0b | -HK$23,718,069,081.00 | 26.9x | -17.5x | 11.6x |
Wed, 03 May 2023 | HK$445.0b | HK$36.7b | -HK$23,526,742,121.00 | 18.1x | -18.9x | 12.1x |
Fri, 31 Mar 2023 | HK$419.6b | HK$35.3b | -HK$25,716,402,512.00 | 12.2x | -16.3x | 11.9x |
Sun, 26 Feb 2023 | HK$403.3b | HK$34.3b | -HK$34,519,333,916.00 | 31.2x | -11.7x | 11.8x |
Tue, 24 Jan 2023 | HK$452.0b | HK$34.9b | -HK$35,245,225,961.00 | 29.8x | -12.8x | 13x |
Thu, 22 Dec 2022 | HK$371.8b | HK$33.6b | -HK$33,898,900,822.00 | 23x | -11x | 11.1x |
Sat, 19 Nov 2022 | HK$379.5b | HK$33.0b | -HK$33,255,843,629.00 | 16.8x | -11.4x | 11.5x |
Mon, 17 Oct 2022 | HK$297.6b | HK$33.7b | -HK$32,213,028,064.00 | 15.5x | -9.2x | 8.8x |
Wed, 14 Sep 2022 | HK$356.2b | HK$34.5b | -HK$33,767,111,427.00 | 16.9x | -10.5x | 10.3x |
Fri, 12 Aug 2022 | HK$339.9b | HK$32.9b | -HK$46,378,297,257.00 | 12.1x | -7.3x | 10.3x |
Sun, 10 Jul 2022 | HK$375.7b | HK$33.1b | -HK$46,688,664,217.00 | 14.4x | -8x | 11.4x |
Tue, 07 Jun 2022 | HK$333.3b | HK$34.3b | -HK$46,192,775,584.00 | 13.5x | -7.2x | 9.7x |
Thu, 05 May 2022 | HK$321.2b | HK$34.4b | -HK$45,764,117,876.00 | 13.5x | -7x | 9.3x |
Sat, 02 Apr 2022 | HK$349.7b | HK$36.5b | -HK$46,136,389,470.00 | 16.5x | -7.6x | 9.6x |
Mon, 28 Feb 2022 | HK$339.1b | HK$33.9b | -HK$31,130,917,530.00 | 13x | -10.9x | 10x |
Wed, 26 Jan 2022 | HK$337.7b | HK$31.2b | -HK$31,952,220,410.00 | 12.4x | -10.6x | 10.8x |
Fri, 24 Dec 2021 | HK$406.1b | HK$31.1b | -HK$31,830,918,782.00 | 13x | -12.8x | 13.1x |
Sun, 21 Nov 2021 | HK$519.0b | HK$31.0b | -HK$31,710,521,061.00 | 13.6x | -16.4x | 16.7x |
Tue, 19 Oct 2021 | HK$502.6b | HK$30.5b | -HK$31,565,405,940.00 | 15x | -15.9x | 16.5x |
Thu, 16 Sep 2021 | HK$500.5b | HK$30.4b | -HK$31,412,511,864.39 | 16.4x | -15.9x | 16.5x |
Sat, 14 Aug 2021 | HK$545.4b | HK$30.2b | -HK$32,058,827,347.35 | 15.3x | -17x | 18x |
-17x
Which industries have driven the changes within the Hong Kong Healthcare industry?
HK Market | -1.71% | |
Healthcare | 4.99% | |
Biotech | 6.48% | |
Biotech | 6.48% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
1801 Innovent Biologics | HK$40.30 | 4.1% +HK$2.6b | 25.2% | PS9.7x | |
9926 Akeso | HK$44.55 | 5.3% +HK$1.9b | 29.3% | PE17.5x | |
2162 Keymed Biosciences | HK$34.20 | 8.7% +HK$760.7m | -30.1% | PS24.6x | |
2511 HighTide Therapeutics | HK$1.86 | 64.6% +HK$375.8m | n/a | PB1.3x | |
2696 Shanghai Henlius Biotech | HK$22.95 | 2.7% +HK$326.1m | 100.6% | PE21x |